Jack Cush is a journalist for RheumNow, specializing in rheumatology and related topics. With a focus on providing up-to-date information to healthcare professionals and patients, Jack covers a wide range of subjects including drug approvals, research findings, treatment guidelines, and emerging trends in the field of rheumatology.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Jack Cush's coverage is heavily focused on healthcare and pharmaceutical topics, specifically in the realm of rheumatology and osteoarthritis. Given that 72% of his articles cite data, it is likely that he would be interested in pitches from experts who can provide evidence-based insights or share new research findings related to these specific medical conditions.
He may also be open to receiving pitches about scientific advancements, particularly those related to drug-induced disorders and non-pharmacological management strategies for musculoskeletal conditions like arthritis.
As Jack does not have a specified geographic focus, sources with international expertise or insights into global trends in rheumatology and medical research could appeal to him.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Jack Cush
UKMC researchers have compared the use of JAK inhibitors versus tumor necrosis factor (TNF) blockers in inflammatory bowel disease (IBD) patients, but failed to see an increase in major adverse cardiovascular events (MACE) in JAKi vs TNFi use in IBD.
Adult-onset Still's disease (AOSD) is systemic autoinflammatory disorder of unknown etiology. It is considered among the febrile autoinflammatory etiologies. Now a cohort study shows that AOSD patients may be enriched in germline variants usually limited to monogenic autoinflammatory disorders.
ACR 2024 starts tomorrow; here are a few previews of Abstracts to be presented. Along with my recommendations of sessions you don't want to miss.
ACR24 Begins today. Many of the great presentations for this meeting come from industry sponsored clinical trials and reports. Often these become the pivotal studies for regulatory approval and the annual congresses are their first look.
ACR Convergence 2024 opened today with a full slate of presentations, posters and specialty meetings. The meeting began with flip, the plenary sessions started at 9AM and the poster session began at 1030 AM. Below are some of the highlights from day one in Washington, DC. Another good way to take in the first day would be to listen or watch the day 1 Recap panel or read the ACR Best Abstracts. If you were there early enough you might have seen the Year in Review, featuring benchmark research singled out by Drs. Louis Bridges (Basic Science) and Michael Pillinger (Clinical)
The RheumNow faculty have parked at the plenaries, trafficked the posters and have been finding the best the meeting offers on the first day at ACR 2024 in Washington, DC. Here are some of the best abstracts from Saturday Nov. 16th. You can also spot these on Twitter by looking for the (#ACRbest) hashtag.
Plenary sessions began the day, followed by thousands on the abstract floor. Here are a few of my favorite presentations from day 2 at ACR 2024.
Here's a collection of some of the best abstracts presented on day 2 of ACR 2024 as selected by the RheumNow faculty. ADD THE FIRST COMMENT
Lots of Lupus research and the New ACR Guidelines on Lupus Nephritis management were presented today. These and other highlights as featured on our Twitter (X) feed from ACR24 in Washington, DC.
Highlights from Day 3 at ACR24 included the plenary session presentation on Nipocalimab (previously reviewed), but the big highlight was the Lupus Nephritis guideline recommendations.
(833) 317-6278 
